Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia
· Delayed Price · Currency is MYR 1.260
+0.030 (2.44%)
At close: Feb 21, 2025
Duopharma Biotech Berhad Income Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 813.7 | 704.73 | 696.72 | 639.18 | 569.9 | Upgrade
|
| Revenue Growth (YoY) | 15.46% | 1.15% | 9.00% | 12.16% | -1.14% | Upgrade
|
| Cost of Revenue | 512.16 | 436.4 | 416.9 | 385.19 | 336.7 | Upgrade
|
| Gross Profit | 301.54 | 268.33 | 279.82 | 253.98 | 233.2 | Upgrade
|
| Selling, General & Admin | 200.58 | 182.72 | 186.59 | 165.78 | 150.81 | Upgrade
|
| Other Operating Expenses | 0.3 | 2.8 | 0.81 | -0.67 | 1.35 | Upgrade
|
| Operating Expenses | 200.89 | 189.61 | 186.91 | 165.22 | 151.35 | Upgrade
|
| Operating Income | 100.65 | 78.71 | 92.91 | 88.77 | 81.86 | Upgrade
|
| Interest Expense | -26.59 | -17.68 | -9.1 | -6.44 | -6.53 | Upgrade
|
| Interest & Investment Income | 5.97 | 2.75 | 1.52 | 1.2 | 1.51 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -0.52 | -0.48 | -0.53 | -0.68 | Upgrade
|
| EBT Excluding Unusual Items | 80.02 | 63.27 | 84.85 | 82.99 | 76.16 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.01 | - | Upgrade
|
| Pretax Income | 80.02 | 63.27 | 84.85 | 82.98 | 76.16 | Upgrade
|
| Income Tax Expense | 17.38 | 10.62 | 14.74 | 17.3 | 17.55 | Upgrade
|
| Net Income | 62.65 | 52.65 | 70.11 | 65.68 | 58.61 | Upgrade
|
| Net Income to Common | 62.65 | 52.65 | 70.11 | 65.68 | 58.61 | Upgrade
|
| Net Income Growth | 19.00% | -24.91% | 6.74% | 12.07% | 6.04% | Upgrade
|
| Shares Outstanding (Basic) | 962 | 959 | 948 | 928 | 928 | Upgrade
|
| Shares Outstanding (Diluted) | 962 | 959 | 948 | 928 | 928 | Upgrade
|
| Shares Change (YoY) | 0.36% | 1.08% | 2.15% | 0.02% | 3.86% | Upgrade
|
| EPS (Basic) | 0.07 | 0.05 | 0.07 | 0.07 | 0.06 | Upgrade
|
| EPS (Diluted) | 0.07 | 0.05 | 0.07 | 0.07 | 0.06 | Upgrade
|
| EPS Growth | 18.53% | -25.71% | 4.49% | 12.05% | 2.09% | Upgrade
|
| Free Cash Flow | 59.84 | 15.86 | 5.08 | -66.16 | 15.24 | Upgrade
|
| Free Cash Flow Per Share | 0.06 | 0.02 | 0.01 | -0.07 | 0.02 | Upgrade
|
| Dividend Per Share | 0.030 | 0.023 | 0.023 | 0.022 | 0.049 | Upgrade
|
| Dividend Growth | 30.43% | 0% | 5.75% | -55.43% | 8.44% | Upgrade
|
| Gross Margin | 37.06% | 38.08% | 40.16% | 39.74% | 40.92% | Upgrade
|
| Operating Margin | 12.37% | 11.17% | 13.34% | 13.89% | 14.36% | Upgrade
|
| Profit Margin | 7.70% | 7.47% | 10.06% | 10.28% | 10.28% | Upgrade
|
| Free Cash Flow Margin | 7.35% | 2.25% | 0.73% | -10.35% | 2.67% | Upgrade
|
| EBITDA | 146.08 | 114.04 | 122.86 | 114.94 | 105.93 | Upgrade
|
| EBITDA Margin | 17.95% | 16.18% | 17.63% | 17.98% | 18.59% | Upgrade
|
| D&A For EBITDA | 45.43 | 35.32 | 29.95 | 26.18 | 24.08 | Upgrade
|
| EBIT | 100.65 | 78.71 | 92.91 | 88.77 | 81.86 | Upgrade
|
| EBIT Margin | 12.37% | 11.17% | 13.34% | 13.89% | 14.36% | Upgrade
|
| Effective Tax Rate | 21.72% | 16.79% | 17.37% | 20.85% | 23.04% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.